Abbott Laboratories (ABT) — Q3 2026 Earnings Preview
Key Points and Preview Table
| Factor | Details & What to Watch |
|---|---|
| Q3 2026 Consensus Revenue | $12,995M (rounded, per consensus) |
| Q3 2026 Consensus EPS (GAAP) | $1.01 |
| Q3 2026 Consensus EBITDA | $3,450M |
| Guidance for FY 2026 | Comparable sales growth: 6.5%–7.5%; Adjusted EPS: $5.45–$5.60 (raised from $5.38–$5.58 in Q1) |
| Q3 2026 Guidance | Adjusted EPS: $1.38–$1.46 |
| Key Focus Areas | Acceleration in Nutrition, Electrophysiology (EP), Core Lab, Cancer Diagnostics; margin expansion |
| Y/Y Comparable | Q3 2025 revenue: $11,393M; Adjusted EPS: $1.30; Q3 2025 organic sales growth: 7.5% (ex-COVID) |
| Recent Actuals | Q2 2026 revenue: $12,593M (+13.0% reported, +4.8% comparable); Adjusted EPS: $1.31 |
| Intra-quarter Commentary | Management reaffirmed confidence in H2 acceleration, highlighted strong sequential improvement in Q2 |
Summary and Conclusions
- Abbott enters Q3 2026 with momentum: Q2 2026 saw sequential improvement in both revenue and earnings, with management raising full-year adjusted EPS guidance and reaffirming top-line growth targets.
- Key drivers for Q3 and H2: The company expects the bulk of H2 acceleration to come from four areas: Nutrition (return to growth), Electrophysiology (EP, with new product launches), Core Lab Diagnostics (lapping China VBP headwinds), and Cancer Diagnostics (Exact Sciences integration, care gap programs).
- Year-over-year comparables: Q3 2025 was a strong quarter (+7.5% organic sales growth ex-COVID), so Q3 2026 faces a tough comp, especially as COVID testing headwinds have largely normalized.
- Consensus expectations: Street is looking for $12,995M in revenue and $1.01 GAAP EPS for Q3 2026, implying continued sequential improvement and successful execution on the H2 acceleration narrative.
- What to watch: Evidence of accelerating growth in Nutrition and EP, margin expansion, continued strong performance in EPD and Medical Devices, and tangible contributions from Exact Sciences/Cancer Diagnostics.
Q3 2026 Preview — Most Important Factors
| Factor | What to Watch / Why It Matters |
|---|---|
| Revenue Growth | Consensus: $12,995M; Guidance: 6.5%–7.5% comparable sales growth for FY26. Sequential improvement expected. |
| Adjusted EPS | Guidance: $1.38–$1.46 for Q3; FY26 raised to $5.45–$5.60. Margin expansion is a key driver. |
| Nutrition Segment | Return to growth in H2 is critical; Q2 saw sequential improvement, but YoY still negative. Volume response to pricing actions and new products will be scrutinized. |
| Electrophysiology (EP) | Acceleration expected with Volt 2.0 and TactiFlex Duo launches. Management expects to outperform market and recapture share in H2. |
| Core Lab Diagnostics | Lapping China VBP headwinds; U.S. and LatAm growth strong. Watch for mid-single-digit growth and share gains. |
| Cancer Diagnostics (Exact Sciences) | Integration progress, care gap program ramp, and Cologuard/Cologuard Plus adoption. H2 growth expected to accelerate to mid-teens. |
| Diabetes Care (Libre) | Q2 growth +9.5% (comparable); management remains bullish, but further acceleration depends on reimbursement expansion (esp. U.S. Type 2 non-insulin). |
| Margin Expansion | Q2 adjusted gross margin 58.0% (+100 bps YoY); continued improvement expected via mix, operational discipline, and Exact Sciences addition. |
| Structural Heart | U.S. franchise under pressure; international strong. Watch for signs of stabilization/improvement in U.S. mitral segment. |
| Guidance Updates | Any changes to FY26 sales/EPS guidance or commentary on 2027 trajectory (management targets 7%+ top-line growth long-term). |
Recent Results — Actuals vs. Consensus
Quarterly Financials (Reported)
| Quarter | Revenue ($M) | YoY Growth | Adjusted EPS | YoY Growth | EBITDA ($M) | Notes |
|---|---|---|---|---|---|---|
| Q2 2026 | 12,593 | +13.0% | $1.31 | +4.0% | 3,275 | +4.8% comparable sales growth |
| Q1 2026 | 11,164 | +7.8% | $1.15 | +5.5% | 2,648 | +3.7% comparable sales growth |
| Q4 2025 | 11,459 | +4.4% | $1.50 | +11.9% | 3,423 | FY25 adj. EPS: $5.15 (+10%) |
| Q3 2025 | 11,393 | +6.9% | $1.30 | +7.4% | 3,035 | Organic sales growth ex-COVID: +7.5% |
Full-Year Financials (Reported)
| Fiscal Year | Revenue ($M) | YoY Growth | Adjusted EPS | YoY Growth | EBITDA ($M) | Notes |
|---|---|---|---|---|---|---|
| 2025 | 44,328 | +5.7% | $5.15 | +10.3% | 11,873 | Organic sales growth ex-COVID: +6.7% |
| 2024 | 41,950 | $4.67 | 10,653 |
Guidance Summary
FY 2026 Guidance (as of Q2 2026)
| Metric | Guidance (FY 2026) | Notes |
|---|---|---|
| Comparable Sales Growth | 6.5%–7.5% | Reaffirmed in Q2; includes Exact Sciences full year |
| Adjusted Diluted EPS | $5.45–$5.60 | Raised from $5.38–$5.58 after Q2 beat |
| Q3 2026 Adjusted EPS | $1.38–$1.46 | |
| Margin Expansion | +100 bps YoY in Q2 gross margin | Continued focus on mix, operational improvements |
Segment Trends and Y/Y Comparables
Segment Performance — Q3 2025 (for Y/Y Comp)
| Segment | Q3 2025 Revenue ($M) | YoY Growth | Organic Growth (ex-COVID) | Notes |
|---|---|---|---|---|
| Nutrition | 2,153 | +4.2% | +4.0% | Led by Adult Nutrition |
| Diagnostics | 2,253 | -6.6% | +0.4% (ex-COVID) | China VBP headwind |
| Established Pharma | 1,511 | +7.5% | +7.1% | Key Emerging Markets double-digit |
| Medical Devices | 5,448 | +14.8% | +12.5% | Diabetes Care, EP, CRM, Heart Failure |
Management Commentary — Recent Tone and Intra-Quarter Color
- Momentum Building: "Our second quarter results reflect the momentum we are building... We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year."
- H2 Acceleration Drivers: "80% of that lift... is really coming from 4 areas: Nutrition, Electrophysiology, Core Lab, and Cancer Diagnostics."
- Nutrition: "Sales increased sequentially by $125 million, driven by improving performance in both Pediatric and Adult Nutrition... I remain encouraged by the progress we are making and confident in our outlook for the second half of the year."
- EP: "We remain confident in our outlook for the second half of the year, including our expectation to begin outperforming the market and recapturing share."
- Cancer Diagnostics: "We continue to expect Cancer Diagnostics growth in the second half to be higher than the first half, supported by increasing volumes from care gap programs, recently launched tests, and continued international adoption."
- Margins: "The improvement was broad-based, reflecting favorable business mix within the legacy Abbott portfolio and from the addition of Exact Sciences as well as the continued operational improvements and disciplined execution of our margin expansion initiatives."
What to Watch for in Q3 2026
- Sequential and YoY Revenue/EPS Growth: Is the company delivering on the expected acceleration, especially in the four highlighted segments?
- Nutrition Recovery: Are volume and sales trends in Nutrition (especially U.S. Adult and Pediatric) showing sustained improvement? Is the 2–4% long-term growth range achievable?
- EP Share Gains: Is Volt 2.0 driving above-market growth and share recapture in the U.S. and Europe?
- Cancer Diagnostics Ramp: Are care gap programs and new user/repeat user growth translating into mid-teens growth for Exact Sciences?
- Margin Expansion: Is the company sustaining or expanding gross and operating margins as guided?
- Structural Heart: Any signs of stabilization or improvement in U.S. mitral segment? Continued double-digit growth internationally?
- Diabetes Care: Is CGM growth re-accelerating, and are there updates on U.S. Type 2 non-insulin coverage or dual-analyte sensor launch?
- Guidance Updates: Any changes to FY26 or early color on FY27 outlook?
Conclusion
Abbott is entering Q3 2026 with positive momentum, having delivered sequential improvement in Q2 and raised its full-year EPS guidance. The Street expects continued acceleration in Q3, with particular focus on Nutrition, Electrophysiology, Core Lab, and Cancer Diagnostics. The company faces a tough y/y comp from Q3 2025, but management has expressed high confidence in achieving its H2 acceleration targets. Margin expansion and successful integration of Exact Sciences are also key themes. The upcoming report will be closely watched for evidence that these drivers are materializing as forecasted.
